A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

NCT06390722 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped strategic decision

Conditions

Atopic Dermatitis
Sleep Disturbance

Interventions

DRUG: Upadacitinib
DRUG: Placebo for Upadacitinib

Sponsor

AbbVie